Literature DB >> 3102453

The pharmacokinetics and tissue penetration of imipenem.

R Wise, I A Donovan, M R Lockley, J Drumm, J M Andrews.   

Abstract

Two studies were performed to investigate the penetration of imipenem into chemically induced inflammatory exudate and into peritoneal fluid. In the first study six volunteers received 500 mg of imipenem, alone and with 500 mg cilastatin. Little difference was noted in the pharmacokinetics or inflammatory fluid penetration of imipenem when given with or without cilastatin. The only significant alteration was the urine recovery (an increase from a mean of 14.7% to 55.6% in the presence of the enzyme inhibitor). The mean inflammatory fluid level of imipenem at 30 min was 6.2 mg/l (or 35% of the plasma level). The inflammatory fluid levels exceeded the plasma levels after 2 h. The overall penetration of imipenem/cilastatin into inflammatory fluid was 67.8% (+/- 13.8) and imipenem alone 73.2% (+/- 13.9). The mean elimination half-life of imipenem from plasma was 1.1 h and from inflammatory fluid 1.4 h (with or without cilastatin). In the second study, 29 patients received 1 g imipenem plus cilastatin before elective surgery and plasma and peritoneal levels were measured over 4 h. There was considerable penetration of the peritoneum, imipenem levels in excess of 30 mg/l being found 15 min after administration declining to 5-7 mg/l by 3-4 h. The mean percentage penetration was 73.4% (+/- 22.1). A brief review of the literature on imipenem tissue penetration is included.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102453     DOI: 10.1093/jac/18.supplement_e.93

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

3.  Pharmacokinetics of imipenem in patients undergoing major colon surgery.

Authors:  M Erttmann; R Krausse; U Ullmann
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

4.  Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).

Authors:  M C Vos; H H Vincent; E P Yzerman
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 6.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration.

Authors:  S A Signs; J S Tan; S J Salstrom; T M File
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

Authors:  J S Solomkin; H H Reinhart; E P Dellinger; J M Bohnen; O D Rotstein; S B Vogel; H H Simms; C S Hill; H S Bjornson; D C Haverstock; H O Coulter; R M Echols
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.